Value of F-18-FDG PET/CT for differentiating diagnosis between malignant and benign primary gastric gastrointestinal mesenchymal tumors: a single-center retrospective study

Background: Malignant primary gastric gastrointestinal stromal tumors (gGISTs) without treatment with imatinib are prone to bleeding and peritoneum implantation during operation. Therefore, preoperative assessment of the malignant potential of gGIST is essential. The use of F-18-fluorodeoxyglucose (F-18-FDG) positron emission tomography (PET) combined with computed tomography (PET/CT) as a non-invasive tool for diagnosis, staging and prognosis evaluation in oncology, may also be useful for gGISTs. In the present study, we analyzed the value of F-18-FIDG PET-CT in assessing the malignant potential of gGISTs before treatment. Methods: Patients who were diagnosed with gGIST by pathology and underwent F-18-FDG PET/CT at the same time were collected. The dinicopathological features of 26 patients with gGISTs were retrospectively analyzed at last. The gGIST risk classification was graded according to the US National Institutes of Health (NIH) GIST risk classification criteria [2008]. Lesions were classified as malignant group (moderate- or high-risk category) and benign group (low- or very low-risk category) according to pathology. The relationship between the maximal standard uptake value (SUVmax) and GIST risk category, tumor diameter, Ki-67 index, and mitotic count was analyzed. The cut-off level of SUVmax for the diagnosis of malignant gGIST with the highest sensitivity was calculated based on the receiver-operating characteristic (ROC) curve. Results: The SUVmax, tumor diameter, Ki-67 index, and mitotic count of the 26 gGIST patients were 5.90 +/- 4.49, 7.40 +/- 4.92 cm, 7.62%+/- 11.76%, (5.96i3.19)/50 high-power field (I IPF), respectively. SUVmax was significantly correlated with GIST risk category, Ki-67 index, and mitotic count (r=0.855, 0.860, and 0.690, all P<0.01) but not with tumor diameter (r=0.383, P=0.054). The SUVmax of gGIST was 7.00 +/- 4.57 in the malignant group (moderate or high NIH risk category in 20 patients), which was significantly different from that (2.25 +/- 0.77) in the benign group (low or extremely low NIH risk category in 6 patients) (t=4.566, P<0.01). ROC curve analysis showed that a SUVmax cut-off of 2.60 was most sensitive for predicting malignant gGIST. When the area under the curve was 0.967, the sensitivity was 100% and the specificity was 83.3%. Conclusions: SUVmax may be used as a complementary indicator for predicting the malignant potential of gGISTs before treatment.